BIB - ProShares Ultra Nasdaq Biotechnology
|Ex-Dividend Date||Sep 21, 2010|
|Trading Day||April 22|
|Day's Range||86.08 - 87.90|
|52-Week Range||56.19 - 113.06|
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
|Asset Class |
|Inception Date |
Apr 8, 2010
|Ticker Symbol |
|Index Tracked |
NASDAQ Biotechnology Index
Top 10 Holdings132.35% of assets
|Nasdaq Biotechnology Index Swap Societe Generale||603698.SS||26.92%|
|Nasdaq Biotechnology Index Swap Ubs Ag||603698.SS||25.08%|
|Nasdaq Biotechnology Index Swap Citibank Na||603698.SS||12.91%|
|Ishares Biotech (Ibb) Swap Goldman Sachs International||603698.SS||11.73%|
|Nasdaq Biotechnology Index Swap Bank Of America Na||603698.SS||10.88%|
|Nasdaq Biotechnology Index Swap Credit Suisse International||603698.SS||8.83%|
|Nasdaq Biotechnology Index Swap Goldman Sachs International||603698.SS||6.30%|
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
Last week witnessed a tug-of-war between bulls and bears.